Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Decreases By 21.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 13,400 shares, a decline of 21.2% from the October 15th total of 17,000 shares. Based on an average daily trading volume, of 43,500 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several large investors have recently bought and sold shares of GNOM. Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter worth $122,000. Centaurus Financial Inc. acquired a new position in Global X Genomics & Biotechnology ETF during the second quarter worth $146,000. James J. Burns & Company LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the second quarter valued at $181,000. Rockefeller Capital Management L.P. bought a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at about $205,000. Finally, Insight Advisors LLC PA raised its position in shares of Global X Genomics & Biotechnology ETF by 59.0% in the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after purchasing an additional 7,861 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ:GNOM traded down $0.40 during trading hours on Friday, hitting $9.80. The stock had a trading volume of 45,216 shares, compared to its average volume of 56,965. Global X Genomics & Biotechnology ETF has a one year low of $9.57 and a one year high of $12.53. The company has a market cap of $71.64 million, a price-to-earnings ratio of -4.36 and a beta of 1.03. The business’s 50 day moving average is $10.89 and its 200-day moving average is $10.86.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.